RadioGel® Human Trials: Vivos Inc.’s Bold Move to Transform Cancer Treatment
Vivos Inc. is making waves in the fight against cancer with its groundbreaking RadioGel® Precision Radionuclide Therapy™. The company’s first human trial in India has already treated five cancer patients using a highly targeted radiation approach. With promising intial results and a U.S. trial at the Mayo Clinic on the horizon, this could be a game-changing moment in oncology.
Let’s dive into the key updates, the science behind RadioGel®, and what these trials mean for the future of cancer treatment.
Vivos Inc Stock Price Today | OTC RDGL Live Ticker – Investing.com
What’s New? Latest Highlights
📅 December 20, 2024 – Vivos Inc. launches first human trial of RadioGel® in India.
🎯 Five human cancer patients treated with targeted precision therapy.
🧪 The U.S. trial at Mayo Clinic aims to treat five patients, pending FDA Investigational Device Exemption (IDE) approval, this initial phase will depend on regulatory clearance.
📚 First human trial in India comprehensive clinical study results expected to be published in a leading medical journal.
In December 2024, Vivos Inc. took its biggest step forward by launching RadioGel® human trials in India. This trial is significant for two reasons:
- It’s the first human application of the company’s precision radionuclide therapy.
- It is to confirm that targeted radiation therapy is not only safe but also effective in treating cancerous lymph nodes.
What Is RadioGel® and How Does It Work?
Here’s a closer look at what makes RadioGel® unique, how the trial was conducted, and what early results mean for future cancer care.
RadioGel® uses Yttrium-90, a radioactive isotope, embedded in a hydrogel matrix to deliver targeted radiation directly to cancerous tissue.
💡 Why is this important?
Traditional radiation therapy often damages healthy cells along with cancerous ones. RadioGel®, however, delivers radiation in a precise, localized manner, reducing side effects and increasing the effectiveness of treatment.
Key Features of RadioGel® Therapy
| Feature | Benefit |
|---|---|
| Targeted Radiation | Minimizes exposure to healthy cells. |
| Yttrium-90 Isotope | Provides a powerful, localized radiation source. |
| Hydrogel Delivery | Ensures radiation stays in the tumor site. |
| Precision Placement | Allows doctors to treat hard-to-reach cancers near critical organ structures. |
This next-generation cancer therapy is especially promising for inoperable tumors and recurrent cancers, where traditional treatments may fall short.
What Happened in the India Trials?
The first human trial in India focused on patients with cancerous lymph nodes, a notoriously challenging area to treat. Here’s how the trial unfolded:
1️⃣ Patient Selection: Five patients were chosen based on their cancer profiles and their suitability for localized radiation therapy.
2️⃣ Treatment Process: Physicians injected RadioGel® directly into the affected lymph nodes, ensuring that radiation was delivered exactly where it was needed.
3️⃣ Safety Measures: The trial prioritized patient safety, with rigorous monitoring to ensure the initial results show no adverse effects from the treatment.
Early Results: What We Know So Far
✅ All five patients completed treatment without major side effects.
✅ The therapy successfully delivered radiation to the targeted cancerous tissue.
✅ Patients showed early signs of positive response, with tumors responding as expected.
The trial is expected to complete in 2025, and the results will be submitted for peer-reviewed publication in a top medical journal.
Why India? The Strategic Choice for a Global Impact
Choosing India as the launch site for the first human RadioGel® trial was a strategic move by Vivos Inc. Here’s why:
🌐 Global Access: India’s large patient population provides a valuable testing ground for treatments that could be rolled out globally.
💰 Cost-Effective Trials: Clinical trials in India are more affordable, allowing Vivos Inc. to test its technology without the massive costs associated with U.S. trials.
📊 Regulatory Leverage: Success in India gives the company a stronger position when seeking approvals from global regulatory bodies, including the FDA.
Next Stop: Mayo Clinic U.S. Trials
Following the success of the India trial, Vivos Inc. is gearing up for a U.S. trial at the Mayo Clinic—one of the most prestigious medical institutions in the world. The Mayo Clinic trial will be critical for obtaining FDA approval for commercialization of RadioGel® and expanding the use of RadioGel® in the U.S.
U.S. Trial Overview
| Detail | Description |
|---|---|
| Location | Mayo Clinic, U.S. |
| Number of Patients | Up to 5 |
| Cancer Focus | Lymph nodes located in the head or neck region |
| Timeline | Seeking approval in 2025 |
| Study Goals | Safety, efficacy, and long-term outcomes |
Why Mayo Clinic Matters
💼 Prestigious Institution: Mayo Clinic is a globally respected leader in medical research.
📋 High Standards: The clinic’s rigorous protocols ensure that the trial meets the highest scientific standards.
📈 Regulatory Influence: Positive results from this trial could fast-track FDA market approval, opening the door to wider commercial use.
The Future of Cancer Treatment
The human trials for RadioGel® mark a turning point in cancer care. Here’s why this breakthrough therapy matters:
1️⃣ Precision Treatment: RadioGel® delivers highly targeted radiation to cancer cells, reducing collateral damage to healthy tissue.
2️⃣ Safety & Efficacy: The early trial results are to confirm that the therapy is safe, while also monitoring device effectiveness.
3️⃣ Global Reach: Success in both India and the U.S. could pave the way for worldwide adoption of this therapy.
If successful, RadioGel® could become a standard treatment option for patients with hard-to-treat cancers, such as inoperable tumors and metastatic disease.
Final Thoughts: RadioGel®’s Potential Impact
With human trials underway in India and a Mayo Clinic trial on the horizon, Vivos Inc. is positioning itself as a leader in precision cancer therapy. By 2025, the company could publish peer-reviewed results that solidify RadioGel® as a game-changer in oncology. The future of cancer treatment may well be glowing with promise, thanks to this innovative approach to precision radiation therapy.
For an in-depth exploration of Vivos Inc.’s groundbreaking advancements with RadioGel™ and IsoPet®, including recent FDA designations, executive leadership updates, please refer to our previous article. Vivos Inc. Innovation in Precision Radionuclide Therapy ‣ TradersQue covers the comprehensive developments that have positioned Vivos Inc. at the cutting edge of medical and veterinary oncology innovation.
About Vivos Inc.
Vivos Inc. has developed an Yttrium-90-based injectable Precision Radionuclide Therapy™ medical device to treat tumors in animals (IsoPet®) and humans (RadioGel®). Using the company’s proprietary hydrogel technology, PRnT™ uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area. This allows the safe delivery of higher doses needed for treating non-resectable and radiation-resistant cancers.
RadioGel® Technology
RadioGel® is a hydrogel liquid containing yttrium-90 phosphate microparticles, administered directly into a tumor. After injection, it gels within the tumor interstitial spaces to keep the radiation sources in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area, minimizing adverse effects on normal organs and tissues. The short half-life of RadioGel® ensures that more than 90% of its therapeutic radiation is delivered within 10 days, allowing for outpatient procedures without risk to family members.
IsoPet® for Veterinary Use
IsoPet® uses the same technology as RadioGel® for treating animals. It has been tested successfully on feline sarcoma at Washington State University and on canine soft tissue sarcomas at the University of Missouri. The FDA has classified IsoPet® as a medical device and does not require pre-market approval for veterinary use, allowing for revenue generation through sales to university hospitals and private clinics.
Vivos Inc. | RadioGel™ | IsoPet® – (OTCMKTS: RDGL)
Meet the Visionaries Behind Vivos Inc.
Meet the innovative minds driving Vivos Inc. forward in the fight against cancer. Our dedicated team combines expertise, passion, and cutting-edge technology to revolutionize cancer treatment. Learn more about our leaders and their groundbreaking work by visiting Meet The Team | RadioGel™
Disclaimer: This article includes paid promotions. We may receive compensation for promoting certain securities. This could influence our content. Please perform your own due diligence and consult with a financial advisor before making any investment decisions.
